Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk ...

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Loss-of-function variants in the ELP1 gene are the most prevalent predisposing genetic factors in childhood medulloblastoma, ...

Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer characterized by very poor prognosis and resistance to immunotherapy due to an immunosuppressive tumor microenvironment, which includes ...

Protier Biotech Inc. has patented protein/nucleic acid degraders comprising cereblon (CRBN)-binding agents covalently bound to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A ...

Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of ...

Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc. exclusive worldwide rights to OncoACP3, ...

London-based Livanova plc. has petitioned the U.S. CMS to cover vagus nerve stimulation device for treatment-resistant ...

The trade wars spanning the globe lined up some unlikely-seeming adversaries, and such is the case in the trade scrum between ...

Myosin Therapeutics Inc. has obtained IND clearance by the FDA for MT-125. A phase I study will evaluate MT-125 in ...

Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial of TPIP in pulmonary arterial hypertension a “clear and ...